First Participant Dosed in Phase 1 Clinical Trial for Investigational Therapy for Multiple Sclerosis
Cyxone has just announced that the first person has been dosed in their Phase 1 clinical trial for Multiple Sclerosis (MS). This trial is investigating the effect of T20K. It…